ReviewStem cell research & therapy2025
Stem cell therapy: a novel frontier in the treatment of liver fibrosis/cirrhosis.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesenchymal stem cells and extracellular vesicles for MAFLD: from biological mechanisms to translational prospects.Stem cell research & therapy · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis and cirrhosis are characterized by the excessive accumulation of extracellular matrix (ECM) in the liver, and they represent significant global health concerns due to their increasing prevalence worldwide. Traditional therapeutic approaches, such as liver transplantation, are limited by donor availability and potential complications. Stem cell therapy has emerged as a promising alternative, offering the potential for liver regeneration and repair. This paper reviews the latest advancements in stem cell therapy for liver fibrosis and cirrhosis, drawing from recent clinical trials and laboratory studies. We explore various stem cell types, evaluating their efficacy, safety, and mechanisms of action in liver repair. Our findings suggest that stem cell therapy, with its anti-fibrotic properties, immunomodulatory effects, and ability to promote hepatocyte regeneration, holds significant promise for the future of liver disease treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.